Epigenetics and immunotherapy in colorectal cancer: progress and promise.
Clin Epigenetics
; 16(1): 123, 2024 Sep 10.
Article
em En
| MEDLINE
| ID: mdl-39252116
ABSTRACT
Colorectal cancer (CRC) is a common malignant tumor with the third and second highest incidence and mortality rates among various malignant tumors. Despite significant advancements in the present therapy for CRC, the majority of CRC cases feature proficient mismatch repair/microsatellite stability and have no response to immunotherapy. Therefore, the search for new treatment options holds immense importance in the diagnosis and treatment of CRC. In recent years, clinical research on immunotherapy combined with epigenetic therapy has gradually increased, which may bring hope for these patients. This review explores the role of epigenetic regulation in exerting antitumor effects through its action on immune cell function and highlights the potential of certain epigenetic genes that can be used as markers of immunotherapy to predict therapeutic efficacy. We also discuss the application of epigenetic drug sensitization immunotherapy to develop new treatment options combining epigenetic therapy and immunotherapy.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Epigênese Genética
/
Imunoterapia
Limite:
Humans
Idioma:
En
Revista:
Clin Epigenetics
/
Clin. epigenet. (Internet)
/
Clinical epigenetics (Internet)
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Alemanha